The right test, the right patient
Comprehensive, cell-free DNA testing
Faster and less invasive than traditional biopsy testing, Mayo Clinic Laboratories’ liquid biopsy panel is a cell-free DNA test that uses next-generation sequencing to evaluate peripheral blood for 33 genes. The genes included in our panel are a condensed, yet comprehensive group of National Comprehensive Cancer Network (NCCN) Guidelines-targeted genes and genes associated with approved FDA therapies.
The assay detects for single nucleotide variants, insertions, and deletions, as well as translocations and microsatellite instability (MSI). Requiring a DNA input of 20 nanograms, the lower input requirement of our assay may lead to lower sample rejection rates. This test also includes a detailed result report containing information on medications to help guide treatment.
Learn more about our full suite of MayoComplete next-generation sequencing panels for hematologic and oncologic conditions.
When to consider testing
For certain patients not able to undergo traditional tissue-based biopsy, liquid biopsy testing can provide fast, accurate answers. Instances in which liquid biopsy testing might be used include:
Full-spectrum cancer testing in one laboratory
Mayo Clinic Laboratories is committed to meeting the needs of our patients and developing a patient-first test menu. Our full suite of pan cancer test offerings, including MayoComplete Solid Tumor Panel, MayoComplete Liquid Biopsy Panel, and MayoComplete targeted panels, provide patients with complementary, comprehensive testing across an array of malignancies. Our panels were thoughtfully designed to only include genes associated with actionable answers for patients.